RxDoctor Payments Data

Steven Tucker, MD

Ophthalmology · Richmond, VANPI 1548655608

Payments from drug & device makers

$1,585in general payments, 2019–2025

Across 58 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$375
  • AbbVie$299
  • Alcon$283
  • Sun Pharmaceutical Industries Inc.$241
  • Ocular Therapeutix, Inc.$63
  • Harrow Eye, LLC$49
  • plus $274 from 11 others

What the payments were for

  • Speaking & faculty fees$392%
  • Food & beverage$1,54698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,585 in reported general payments places this provider in the 60th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$595,764
Medicare patients
1,802
Services billed
4,761

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine120$117,178
Cyclosporine76$37,786
XiidraLifitegrast30$28,101
LumiganBimatoprost53$28,055
TyrvayaVarenicline Tartrate23$25,512
RocklatanNetarsudil Mesylat/Latanoprost15$11,546
Latanoprost716$8,584
CombiganBrimonidine Tartrate/Timolol28$8,108
Prednisolone Acetate210$6,310
SimbrinzaBrinzolamide/Brimonidine Tart20$4,011
Tobramycin-DexamethasoneTobramycin/Dexamethasone84$3,749
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat197$3,591
Travoprost11$3,460
Loteprednol Etabonate14$3,298
Brimonidine Tartrate68$2,352

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$299$153,341201 claims
Oyster Point Pharma, Inc.Tyrvaya$39$25,51223 claims
Aerie Pharmaceuticals, Inc.Rocklatan$15$11,54615 claims
AlconSimbrinza$283$4,01120 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$13$3,29814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →